Core Viewpoint - The company is preparing for its 2024 annual shareholder meeting, discussing various proposals including financial reports, investment plans, and the decision not to distribute profits due to negative net income in 2024 [1][2][5]. Group 1: Meeting Agenda and Proposals - The annual shareholder meeting is scheduled for May 22, 2025, in Nanjing, with a half-day duration [1]. - The agenda includes nine proposals, such as the 2024 board work report, annual report, financial budget for 2025, and the investment plan for 2025 [1][2][3]. - The company plans to invest a total of 444 million yuan in 2025, focusing on ongoing projects without new land acquisitions [3][4]. Group 2: Financial Performance - The company reported a net loss of approximately 178.78 million yuan for 2024, leading to a recommendation not to distribute profits [5]. - The total available funds for the company in 2025 are projected to be 1.72 billion yuan, including cash from sales and other activities [4]. Group 3: Independent Directors and Auditors - The company proposes to continue employing Tianheng Accounting Firm for financial auditing in 2025 due to their satisfactory service [6]. - The independent directors' compensation for 2024 is set at 50,000 yuan each [6]. Group 4: Supervisory Board Report - The supervisory board conducted multiple meetings throughout 2024, ensuring compliance with legal and regulatory requirements [11][12]. - The board confirmed that the company’s internal control systems are effective and that there were no violations regarding external guarantees or related party transactions [13][14].

Core Viewpoint - Berkshire Hathaway's stock has significantly outperformed the market this year, showcasing Warren Buffett's continued confidence in the U.S. economy despite global economic challenges [1]. Group 1: Views on the U.S. Economy - Buffett has historically expressed unwavering confidence in the U.S. economy, even during crises like the 2008 financial crisis and the COVID-19 pandemic [3][4]. - The IMF has downgraded U.S. economic growth forecasts to 1.8%, citing increased policy uncertainty, trade tensions, and weakening demand as primary factors [3]. - Recent data indicates a 0.3% annualized contraction in U.S. GDP for Q1, marking the first decline since early 2022, raising concerns about potential recession [4]. Group 2: Cash and Buybacks - Berkshire's growing cash reserves are a focal point for investors, with questions about future cash deployment amid anticipated declining interest rates [5]. - Year-to-date, Berkshire's stock has risen 16%, outperforming the S&P 500 by nearly 23 percentage points and the Nasdaq by about 27 percentage points [5]. - Berkshire holds $30.08 billion in U.S. Treasury securities, representing 4.89% of the total short-term U.S. debt, while buyback activity has slowed, with only $2.9 billion in stock repurchased in 2024, the lowest since 2018 [5]. Group 3: Future Investment Plans - Despite reducing equity holdings since 2022, Buffett remains committed to investing primarily in stocks rather than cash, emphasizing a long-term investment strategy [6]. - Buffett has indicated a preference for acquiring stakes in good companies rather than holding cash equivalents, reinforcing his value-oriented investment philosophy [6]. - Recent investments include a significant stake in five major Japanese companies, with a total investment of $13.8 billion now valued at $23.5 billion [7]. Group 4: Artificial Intelligence Evaluation - Buffett has acknowledged the transformative potential of artificial intelligence, expressing both excitement and concern about its implications [9]. - He highlighted the risks of AI-related scams and the potential for significant societal impact, indicating a cautious approach to discussing AI's future [9]. - The discussion on AI is expected to be further elaborated by Berkshire's vice chairman, Greg Abel, during the upcoming shareholder meeting [9]. Group 5: Succession and Company Future - As Buffett approaches 95, succession planning has become a critical topic, with Greg Abel positioned as a potential successor [10]. - Buffett reassured shareholders that the future management team is well-prepared to uphold the company's principles and respond to significant investment opportunities [10][11]. - The company has addressed long-term management strategies, ensuring continuity in its investment philosophy and operational integrity [10].

文 | 银行螺丝钉 （转载请注明出处） 有偏离自己制定的投资计划。 第二是我们在定投的时候，要综合考虑自 己的心理承受能力和投入的资金量。 定投开始时投入的钱不多，所以心理压 力会小一点。 IEA J V L J F J F J F J F J L L J ▼点击阅读原 文，免费学习大额家庭资产配置课程 而如果遇到下跌的时候感到恐慌，往往 说明这个时候你投的钱可能超出自己的 心理承受能力了。 投的钱越多，心理压力越大。这时候可 能就容易头脑一昏，做出错误的决策。 因此,最好用长期不用的闲钱投资,这笔 钱是遇到下跌你也不慌的金额。 说一个极端的例子，就是这笔钱哪怕打 水漂了，你也不会觉得心疼的那种。 这种程度的资金,做长期投资更容易坚 挂下求。 ...

Financial Data and Key Metrics Changes - In Q1 2025, the company reported worldwide sales of $21.9 billion, reflecting a 4.2% increase despite a 470 basis point headwind from Stelara [25][27] - Net earnings for the quarter were $11 billion, with diluted earnings per share at $4.54, significantly up from $1.34 a year ago, primarily due to a $7 billion reversal related to the talc settlement proposal [26][40] - Adjusted net earnings were $6.7 billion, with adjusted diluted earnings per share at $2.77, representing increases of 1.9% and 2.2% respectively compared to Q1 2024 [26][40] Business Line Data and Key Metrics Changes - Innovative Medicine achieved worldwide sales of $13.9 billion, up 4.2%, with U.S. growth at 6.3% and international growth at 1.5% [27][30] - In Oncology, DARZALEX grew by 22.5%, while PERVICTI saw over 100% growth, driven by share gains and capacity expansion [28][30] - MedTech reported worldwide sales of $8 billion, increasing by 4.1%, with U.S. growth at 5.1% and international growth at 3% [32][33] Market Data and Key Metrics Changes - U.S. sales growth was 5.9%, while international sales growth was 2.1% [25] - The company experienced a positive impact of 90 basis points from acquisitions and divestitures on worldwide growth [25] - MedTech performance was affected by one-time events, particularly in orthopedics, which declined by 3.1% [37] Company Strategy and Development Direction - The company plans to invest over $55 billion in the U.S. over the next four years to enhance manufacturing, R&D, and technology [13][15] - The acquisition of Intra Cellular Therapies is expected to bolster the neuroscience portfolio, with CAPLYTA projected to have over $5 billion in peak year sales potential [16][46] - A restructuring program is being implemented to simplify operations in the surgery business, with an estimated cost of $900 million [44][45] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving 2025 guidance despite challenges from Stelara's biosimilars and Part D redesign [7][76] - The company anticipates higher growth in the second half of the year, particularly in MedTech, as new products gain traction [44][51] - Management highlighted the resilience of the diversified business model in navigating headwinds and delivering on financial commitments [57] Other Important Information - The company increased its dividend for the 63rd consecutive year, reflecting its commitment to returning capital to shareholders [17][46] - The effective tax rate for the quarter was 19.3%, influenced by the reversal of the talc settlement accrual [40] Q&A Session Summary Question: Impact of tariffs on guidance - The company discussed $400 million in tariffs primarily affecting MedTech, with limited price leverage to pass costs to customers [58][60] Question: Gross margins in the quarter - Management noted that gross margins were impacted by the loss of Stelara and Part D redesign, with expectations for improvement moving forward [68][70] Question: Erosion of Stelara due to biosimilars - Management indicated that the impact of Stelara's biosimilars was in line with expectations, with overall business growth remaining strong despite this headwind [74][76] Question: Recession impact on business - Management expressed confidence in the healthcare sector's resilience during economic downturns, noting that elective procedures may be delayed but not abandoned [81][84] Question: Section 232 potential pharma tariffs - Management is analyzing the potential impact of Section 232 tariffs, emphasizing the importance of partnering with the administration to mitigate supply chain vulnerabilities [90]

Group 1 - The company held its 37th meeting of the 8th Board of Directors on March 31, 2025, with all 6 participating directors voting [1][2] - The board approved the revision of the internal audit system, with a unanimous vote of 6 in favor [1] - The company approved its investment plan for 2025, totaling 331.3686 million yuan, which includes 288.4672 million yuan for major projects and 42.9014 million yuan for general updates and renovations [1][2] Group 2 - The company authorized the general manager to adjust specific investment projects within the approved investment plan to enhance decision-making efficiency, with a unanimous vote of 6 in favor [2] - The board approved the appointment of Mr. Li Gang as the new Chief Financial Officer, following a nomination and review process, with a unanimous vote of 6 in favor [2] - Mr. Li Gang has a background in accounting and has held various positions in finance, including as the financial head of the company [2]

Group 1 - The company is holding its second extraordinary general meeting of shareholders on March 31, 2025, in Deyang, Sichuan [1][3] - The agenda includes reviewing and voting on several proposals, including compensation for directors and supervisors, and financial agreements with banks [3][4] - The company proposes a total compensation plan for directors and supervisors for the year 2024, which includes basic salary and performance-based salary [2][4] Group 2 - The company plans to apply for a comprehensive credit limit not exceeding RMB 10.14 billion from financial institutions to meet operational funding needs [4][6] - The proposed credit will be used for various financial services, including loans, bill issuance, and financial derivatives [4][5] - The company intends to sign financial service agreements with Agricultural Bank, Bank of China, and other banks to establish long-term cooperative relationships [5][6] Group 3 - The company has outlined its investment plan for 2025, which includes 106 fixed asset investment projects totaling RMB 2.089 billion and 4 equity investment projects totaling RMB 372.9 million [6][7] - The investment plan includes 65 new projects with a total investment of RMB 1.325 billion, and the funding sources include self-funding and bank loans [7]